This is an open-label single-cohort multi-institutional study of 131I-Apamistamab followed by CAR-T cell therapy for patients with (R/R) DLBCL. Patients will receive a 50 mCi single planned 131I-Apamistamab dose prior to CAR-T cell infusion for lymphodepleting conditioning. There will be a 6-patient safety run-in to assess safety.
© 2026 Paid Trials | All Right Reserved.
Step 1: Add a recruitment campaign (optional)
Our expert team has 10+ years running successful recruitment campaigns for clinical research sites
Your plan includes posting your clinical trials on our recruitment portal and mobile apps. Boost your trials with targeted advertising campaigns to reach more participants, faster.
We handle everything: audience targeting, creative development, geo targeting to your site locations, and ongoing optimizations. Qualified participant inquiries flow directly into your dashboard. Inquiries typically begin within a few days and continue throughout the campaign.
